Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that Dr. David Huang, Chief Medical Officer at Motif Bio, has been invited to present a clinical development overview of iclaprim during the formal Symposia session at IDWeek 2017 on October 5, 2017. In addition, Dr. Huang will lead a “Meet-the-Professors Session” in a clinically oriented Q&A session on October 6, 2017.
IDWeek is the combined annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, HIV Medicine Association and Pediatric Infectious Diseases Society. The Symposia session is focused on clinical programmes in late clinical development and closest to regulatory approval.
Commenting on the invitation David Huang, CMO at Motif Bio Plc said: “IDWeek is a major event for infectious disease professionals and I am delighted that the IDWeek Committee have selected iclaprim for presentation. I look forward to presenting the positive data from the REVIVE-1 trial. We believe these data suggest iclaprim may serve as an important differentiated antibiotic option in an era of emerging antibiotic resistant infections.”
